Skip to content
Review

The interplay between chronic inflammation and tumorigenesis: unraveling the inflammation-driven axis.

Aug 2026 · Critical reviews in clinical laboratory sciences · pp. 1-34 · 0 citations · 252 references
Medicine

TL;DR

Inflammatory biomarkers and epigenetic inflammation scores may support cancer risk stratification, early detection, prognostic assessment and treatment monitoring; however, most should be interpreted as complementary laboratory tools rather than stand-alone diagnostic tests, and clinical implementation requires standardized analytical platforms, harmonized cutoff values, demonstration of incremental utility and prospective validation.

Abstract

Chronic inflammation is now recognized as an important factor linking tissue damage to the development of cancer. Epidemiological studies have suggested that 20%-25% of cancers are related to chronic inflammation, as exemplified by chronic hepatitis B infection inducing hepatocellular carcinoma (HCC) or Helicobacter pylori infection inducing the development of gastric cancer. In chronic inflammation, an overexpression of signaling pathways such as NF-κB, JAK/STAT3, MAPK and NLRP3 at the molecular level leads to continuous upregulation of the secretion of pro-inflammatory cytokines and immune-metabolic reprogramming. These processes result in DNA damage, genetic mutations and epigenetic changes, promoting the initiation and progression of tumors. Interactions between pro-inflammatory cytokines and different types of cellular constituents reshape the tumor microenvironment (TME), leading to fibrosis, chaotic angiogenesis, and immune suppression-favoring further immune escape by tumors and perpetuating cancer stemness. Furthermore, through epigenetic as well as other molecular mechanisms, chronic inflammation fosters tumor drug resistance. So far, anti-inflammatory agents (e.g. anti-inflammatory drugs and natural bioactive compounds) as well as forms of dietary intervention have been associated with a reduced risk of cancer development in selected inflammation-associated settings, emphasizing that inflammation control may contribute to cancer prevention when supported by appropriate patient selection and clinical validation. In addition, new anti-inflammatory drug interventions targeting the IL-6/STAT3, NF-κB and NLRP3 pathways have shown good prospects for inhibiting tumors while modulating the immune microenvironment. Inflammatory biomarkers and epigenetic inflammation scores may support cancer risk stratification, early detection, prognostic assessment and treatment monitoring; however, most should be interpreted as complementary laboratory tools rather than stand-alone diagnostic tests, and their clinical implementation requires standardized analytical platforms, harmonized cutoff values, demonstration of incremental utility and prospective validation.

View source

Similar papers

Review Open access Oct 2026

Obesity-driven inflammation and immune dysregulation in cancer development and progression

Obesity increases the risk and progression of at least 13 types of cancer. Although the epidemiologic links between excess adiposity and these cancers are well documented, the biological mechanisms linking obesity to carcinogenesis and tumor progression remain incompletely understood. White adipose tissue in obesity is...

Pritika Pandey, Jeb F. Struder, Erika T. Rezeli et al. · 0 citations
Review Open access Sep 2026

Obesity-associated inflammation and cancer: molecular mechanisms, evidence gaps, and therapeutic opportunities

Obesity, recognized as a significant global public health issue, has garnered widespread attention. The chronic systemic inflammatory state characteristic of obesity may act as a key pathophysiological factor in the development of obesity-related cancers. Based on a structured literature search of peer-reviewed databas...

Jia Meng, Xue-Kai Bao · 0 citations
Review Open access Oct 2026

Colitis-associated colorectal carcinogenesis: molecular mechanisms and therapeutic potential

Chronic colitis is a major risk factor for colorectal cancer (CRC), particularly for colitis-associated colorectal cancer (CAC), where persistent inflammation drives the transition from mucosal injury to malignant transformation. Accumulating evidence indicates that gut microbiota dysbiosis, epithelial barrier disrupti...

Yi Lu, Xi-Xi Wang, C. Yin et al. · 0 citations
Review Oct 2026

Immunosenescence in colorectal cancer: Interplay of microbiota, inflammaging, and metabolic reprogramming.

Colorectal cancer (CRC) represents a major cause of cancer-associated morbidity and mortality worldwide, with significantly higher incidence and lethality in elderly individuals. Growing evidence implicates immunosenescence, the age-dependent functional decline of the immune system, as a key contributor to CRC initiati...

Dong-Jie Wu, Peng-Fei Zhang, Chang-Chun Zeng · 0 citations
Review Open access Oct 2026

Progress in research on gut microbiota regulation of tumorigenesis, progression, and therapeutic response via inflammatory cytokines

Current evidence on how the gut microbiota and inflammatory cytokines jointly regulate tumour development and therapeutic outcomes is summarized and therapeutic strategies that target microbial composition and inflammatory signalling are discussed.

Yan Liu, D. Zang, Jun Chen · 0 citations
Oct 2026

The Gut Microbiota-inflammation-immune Axis in Cancer: Anti-inflammatory Mechanisms and Therapeutic Implications.

Through its mediation between inflammatory and immune pathways, the gut microbiota has proved to be a key regulator of cancer development, progression, and treatment response. Changes in microbial composition known as dysbiosis might facilitate chronic inflammation, immune dysregulation, and genomic instability, thereb...

Neeraja Suresh, Vijay Singh, Anushka Rathore et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.